1. Adelaide Research & Scholarship

Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 14 (Search time: 0.005 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2016Gender and tachycardia: independent modulation of platelet reactivity in patients with atrial fibrillationProcter, N.; Ball, J.; Ngo, D.; Isenberg, J.; Hylek, E.; Chirkov, Y.; Stewart, S.; Horowitz, J.
2018Asymmetric and symmetric dimethylarginine predict outcomes in patients with atrial fibrillation: an ARISTOTLE substudyHorowitz, J.; De Caterina, R.; Heresztyn, T.; Alexander, J.; Andersson, U.; Lopes, R.; Steg, P.; Hylek, E.; Mohan, P.; Hanna, M.; Jansky, P.; Granger, C.; Wallentin, L.
2014High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: Insights from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trialHijazi, Z.; Siegbahn, A.; Andersson, U.; Granger, C.; Alexander, J.; Atar, D.; Gersh, B.; Mohan, P.; Harjola, V.; Horowitz, J.; Husted, S.; Hylek, E.; Lopes, R.; McMurray, J.; Wallentin, L.
2015Impaired platelet nitric oxide response in patients with new onset atrial fibrillationProcter, N.; Ball, J.; Liu, S.; Hurst, N.; Nooney, V.; Goh, V.; Stafford, I.; Heresztyn, T.; Carrington, M.; Ngo, D.; Hylek, E.; Isenberg, J.; Chirkov, Y.; Stewart, S.; Horowitz, J.
2014Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trialWallentin, L.; Hijazi, Z.; Andersson, U.; Alexander, J.; De Caterina, R.; Hanna, M.; Horowitz, J.; Hylek, E.; Lopes, R.; Åsberg, S.; Granger, C.; Siegbahn, A.
2016History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trialDe Caterina, R.; Andersson, U.; Alexander, J.; Al-Khatib, S.; Bahit, M.; Goto, S.; Hanna, M.; Held, C.; Hohnloser, S.; Hylek, E.; Lanas, F.; Lopes, R.; López-Sendón, J.; Renda, G.; Horowitz, J.; Granger, C.; Wallentin, L.
2016Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillationHijazi, Z.; Aulin, J.; Andersson, U.; Alexander, J.; Gersh, B.; Granger, C.; Hanna, M.; Horowitz, J.; Hylek, E.; Lopes, R.; Siegbahn, A.; Wallentin, L.
2016Platelet hyperaggregability in patients with atrial fibrillation: Evidence of a background proinflammatory milieuProcter, N.; Ball, J.; Ngo, D.; Chirkov, Y.; Isenberg, J.; Hylek, E.; Stewart, S.; Horowitz, J.
2015Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudyHijazi, Z.; Siegbahn, A.; Andersson, U.; Lindahl, B.; Granger, C.; Alexander, J.; Atar, D.; Gersh, B.; Hanna, M.; Harjola, V.; Horowitz, J.; Husted, S.; Hylek, E.; Lopes, R.; McMurray, J.; Wallentin, L.
2010Apixaban for reduction in stroke and other ThromboemboLic events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationaleLopes, R.; Alexander, J.; Al-Khatib, S.; Ansell, J.; Diaz, R.; Easton, J.; Gersh, B.; Granger, C.; Hanna, M.; Horowitz, J.; Hylek, E.; McMurray, J.; Verheugt, F.; Wallentin, L.

Discover